Prostate Specific Antigen antibody

Catalog No. ABIN1042484

The Mouse Monoclonal anti-Prostate Specific Antigen antibody has been validated for ELISA, WB, IHC (p), FACS, ICC and IHC (fro). It is suitable to detect Prostate Specific Antigen in samples from Human.

Quick Overview for Prostate Specific Antigen antibody (ABIN1042484)

Target: Prostate Specific Antigen (PSA)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Prostate Specific Antigen antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: C3F12

Product Details anti-Prostate Specific Antigen Antibody

Characteristics: Tumour marker

Purification: Purified

Isotype: IgG1

Application Details

Application Notes: C3F12 is suitable for immunocytochemistry, immuno-histochemistry on frozen and paraffin-embedded tissues, ELISA, Western blotting and flow cytometry. Optimal antibody dilution should be determined by titration.

Comment:

Monoclonal antibody to prostate specific antigen (PSA), protein A purified from mouse ascites in 50mM posphate buffer pH 7.4 containing 0.1 mM NaCl and 0.09 % sodium azide.

Restrictions: For Research Use only

Handling

Buffer: PBS containing 0.09% sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for Prostate Specific Antigen

Target: Prostate Specific Antigen (PSA)

Alternative Name: PSA

Background: Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a 33 kDa glycoprotein encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland. PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders.

Pathways: Complement System